CL2019002610A1 - Anticuerpos de unión a vista a ph ácido. - Google Patents

Anticuerpos de unión a vista a ph ácido.

Info

Publication number
CL2019002610A1
CL2019002610A1 CL2019002610A CL2019002610A CL2019002610A1 CL 2019002610 A1 CL2019002610 A1 CL 2019002610A1 CL 2019002610 A CL2019002610 A CL 2019002610A CL 2019002610 A CL2019002610 A CL 2019002610A CL 2019002610 A1 CL2019002610 A1 CL 2019002610A1
Authority
CL
Chile
Prior art keywords
acid
sight
binding antibodies
antibodies
joined
Prior art date
Application number
CL2019002610A
Other languages
English (en)
Spanish (es)
Inventor
Robert J Johnston
Arvind Rajpal
Paul O Sheppard
Luis Borges
Andrew Rankin
Keith Sadoon Bahjat
Alan J Korman
Andy X Deng
lin hui Su
Ginger RAKESTRAW
Original Assignee
Five Prime Therapeutics Inc
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Prime Therapeutics Inc, Bristol Myers Squibb Co filed Critical Five Prime Therapeutics Inc
Publication of CL2019002610A1 publication Critical patent/CL2019002610A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2812—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Transplantation (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CL2019002610A 2017-03-14 2019-09-12 Anticuerpos de unión a vista a ph ácido. CL2019002610A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762471196P 2017-03-14 2017-03-14
US201862636746P 2018-02-28 2018-02-28

Publications (1)

Publication Number Publication Date
CL2019002610A1 true CL2019002610A1 (es) 2019-11-29

Family

ID=63522565

Family Applications (2)

Application Number Title Priority Date Filing Date
CL2019002610A CL2019002610A1 (es) 2017-03-14 2019-09-12 Anticuerpos de unión a vista a ph ácido.
CL2021002769A CL2021002769A1 (es) 2017-03-14 2021-10-21 Anticuerpos de unión a vista (divisional solicitud n° 201902610)

Family Applications After (1)

Application Number Title Priority Date Filing Date
CL2021002769A CL2021002769A1 (es) 2017-03-14 2021-10-21 Anticuerpos de unión a vista (divisional solicitud n° 201902610)

Country Status (18)

Country Link
US (3) US11603406B2 (enExample)
EP (1) EP3595720A4 (enExample)
JP (3) JP7211961B2 (enExample)
KR (2) KR20240151866A (enExample)
CN (2) CN110740749B (enExample)
AU (2) AU2018236218B2 (enExample)
BR (1) BR112019019108A2 (enExample)
CA (1) CA3054067A1 (enExample)
CL (2) CL2019002610A1 (enExample)
CO (1) CO2019010943A2 (enExample)
IL (2) IL326895A (enExample)
MX (1) MX2024003316A (enExample)
MY (1) MY200609A (enExample)
PE (2) PE20250933A1 (enExample)
SG (1) SG11201907848YA (enExample)
TW (3) TWI825010B (enExample)
WO (1) WO2018169993A1 (enExample)
ZA (1) ZA201905525B (enExample)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4793360A2 (en) 2006-03-31 2026-08-19 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP3127921A1 (en) 2007-09-26 2017-02-08 Chugai Seiyaku Kabushiki Kaisha Method of modifying isoelectric point of antibody via amino acid substition in cdr
TW201920257A (zh) 2008-04-11 2019-06-01 日商中外製藥股份有限公司 重複結合複數個抗原的抗原結合分子
TWI654203B (zh) 2010-11-30 2019-03-21 Chugai Seiyaku Kabushiki Kaisha 具有鈣依存性的抗原結合能力之抗體
SG10201609665PA (en) 2011-02-25 2017-01-27 Chugai Pharmaceutical Co Ltd FcɣRIIb-SPECIFIC Fc ANTIBODY
JP6322411B2 (ja) 2011-09-30 2018-05-09 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
KR20210074395A (ko) 2011-11-30 2021-06-21 추가이 세이야쿠 가부시키가이샤 면역 복합체를 형성하는 세포내로의 운반체（캐리어）를 포함하는 의약
EP4624490A3 (en) 2012-02-09 2025-11-05 Chugai Seiyaku Kabushiki Kaisha Modified fc region of antibody
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
TWI855488B (zh) 2012-08-24 2024-09-11 日商中外製藥股份有限公司 FcγRIIb特異性Fc區域變異體
ES2812208T3 (es) * 2013-03-14 2021-03-16 Bristol Myers Squibb Co Combinación de un agonista de DR5 y un antagonista de anti-PD-1 y métodos de uso
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
MX2017005774A (es) 2014-12-19 2017-07-28 Chugai Pharmaceutical Co Ltd Anticuerpos antimiostatina, polipeptidos que contienen regiones fc variantes, y metodos de uso.
EA201791366A1 (ru) 2014-12-19 2018-02-28 Чугаи Сейяку Кабусики Кайся Антитела к c5 и способы их применения
CN114773469B (zh) 2015-02-05 2025-12-19 中外制药株式会社 包含离子浓度依赖性的抗原结合结构域的抗体，fc区变体，il-8-结合抗体及其应用
EP3394098A4 (en) 2015-12-25 2019-11-13 Chugai Seiyaku Kabushiki Kaisha ANTI-MYOSTATIN ANTIBODIES AND METHOD OF USE
CN109071631B (zh) 2016-03-14 2023-07-14 奥斯陆大学 具有改变的FcRn结合的工程化免疫球蛋白
CN116271014A (zh) 2016-08-05 2023-06-23 中外制药株式会社 用于预防或治疗il-8相关疾病的组合物
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
WO2018139623A1 (en) 2017-01-30 2018-08-02 Chugai Seiyaku Kabushiki Kaisha Anti-sclerostin antibodies and methods of use
PE20250933A1 (es) * 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
US11220550B2 (en) 2017-05-25 2022-01-11 Bristol-Myers Squibb Company Antagonistic anti-CD40 antibodies and methods of antagonizing CD40 activity
SG11202008593PA (en) 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
US20190300610A1 (en) * 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
GB201814562D0 (en) 2018-09-07 2018-10-24 Hummingbird Bioscience Pte Ltd Vista antigen-binding molecules
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
KR20250024129A (ko) * 2018-07-20 2025-02-18 피에르 파브르 메디카먼트 Vista의 수용체
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
CA3149719A1 (en) * 2019-09-19 2021-03-25 Bristol-Myers Squibb Company Antibodies binding to vista at acidic ph
BR112022012010A2 (pt) 2019-12-18 2022-08-30 Hoffmann La Roche Anticorpos, ácido nucleico isolado, célula hospedeira, formulação farmacêutica, uso do anticorpo, método de produção de um anticorpo, método de tratamento de um indivíduo que tem câncer e método de tratamento de um indivíduo que tem uma doença inflamatória ou autoimune
BR112023016533A2 (pt) * 2021-02-18 2023-11-21 Kineta Inc Anticorpos antivista e usos dos mesmos
EP4373848A2 (en) 2021-07-22 2024-05-29 University of Dundee Therapeutic muteins

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4997913A (en) 1986-06-30 1991-03-05 Oncogen pH-sensitive immunoconjugates and methods for their use in tumor therapy
US5605821A (en) 1989-03-08 1997-02-25 Board Of Regents Of The University Of Oklahoma Expression control sequences of the P-selectin gene
DK0714912T3 (da) 1990-07-17 2003-02-03 Univ Oklahoma Funktionelt aktive selektin-deriverede peptider og ligander for GMP-140
US5843707A (en) 1992-10-23 1998-12-01 Genetics Institute, Inc. Nucleic acid encoding a novel P-selectin ligand protein
US6277975B1 (en) 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
AU677261B2 (en) 1992-10-23 1997-04-17 Genetics Institute, Llc Novel P-selectin ligand protein
EP0668907A1 (en) 1992-11-16 1995-08-30 Board Of Regents Of The University Of Oklahoma Glycoprotein ligand for p-selectin and methods of use thereof
WO1995030001A2 (en) 1994-04-28 1995-11-09 Genetics Institute, Inc. Novel p-selectin ligand protein
DE69630307T2 (de) 1995-08-03 2004-07-15 The Board Of Regents Of The University Of Oklahoma, Norman O-glycaninhibitoren von selectinvermittelten entzüngen
WO1997009068A2 (en) 1995-09-01 1997-03-13 University Of Washington Interactive molecular conjugates
EP1040117A4 (en) 1997-12-18 2005-03-09 Human Genome Sciences Inc 110 HUMAN SECRETED PROTEINS
CA2331386A1 (en) 1998-06-26 2000-01-06 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
NZ510464A (en) 1998-09-01 2004-05-28 Genentech Inc Further pro polypeptides and sequences thereof
AU2883700A (en) 1999-06-23 2001-01-09 Genentech Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
EP1200582A2 (en) 1999-07-08 2002-05-02 Sagami Chemical Research Center Human proteins having hydrophobic domains and dnas encoding these proteins
PL362227A1 (en) 2000-03-24 2004-10-18 Genetic Institute, Llc A novel p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
US20040116333A1 (en) 2001-08-03 2004-06-17 Rong-Hwa Lin Modulators of P-selectin glycoprotein ligand 1
US7744888B2 (en) 2001-08-03 2010-06-29 Abgenomics Cooperatief U.A. Methods of modulating T cell or natural killer cell activity with anti-P-selectin glycoprotein ligand 1 antibodies
AU2003256266A1 (en) 2002-06-12 2003-12-31 Genencor International, Inc. Methods and compositions for milieu-dependent binding of a targeted agent to a target
US20040152105A1 (en) 2002-09-06 2004-08-05 Cytos Biotechnology Ag. Immune modulatory compounds and methods
US20050260711A1 (en) * 2004-03-30 2005-11-24 Deepshikha Datta Modulating pH-sensitive binding using non-natural amino acids
MY148646A (en) 2004-05-10 2013-05-15 Abgenomics Cooperatief Ua Anti-psgl-1 antibodies
BRPI0510561A (pt) 2004-05-11 2007-11-20 Abgenomics Corp epìtopos que induzem morte de célula t
PL1781682T3 (pl) 2004-06-24 2013-08-30 Mayo Found Medical Education & Res Polipeptyd kostymulujący B7-H5
US8231872B2 (en) 2005-04-25 2012-07-31 The Trustees Of Dartmouth College Regulatory T cell mediator proteins and uses thereof
WO2006116181A2 (en) 2005-04-25 2006-11-02 Trustees Of Dartmouth College Regulatory t cell mediator proteins and uses thereof
WO2007033959A2 (en) 2005-09-19 2007-03-29 Vib Vzw Use of p-selectin glycoprotein ligand 1 in modulation of hematogenous metastasis of lymphomas
WO2007067984A2 (en) 2005-12-09 2007-06-14 Wyeth Neutralizing antibodies against primate psgl-1 and uses therefor
US7655778B2 (en) 2006-02-28 2010-02-02 Curonix Co., Ltd. SISP-1, a novel p53 target gene and use thereof
US20100129368A9 (en) * 2006-10-11 2010-05-27 Ablynx N.V. Amino acid sequences that bind to serum proteins in a manner that is essentially independent of the pH, compounds comprising the same, and uses thereof
US8119130B2 (en) 2007-07-25 2012-02-21 Medimmune Limited Targeted binding agents directed to KDR and uses thereof—035
WO2009100110A1 (en) 2008-02-05 2009-08-13 Medarex, Inc. Alpha 5 - beta 1 antibodies and their uses
AU2009221915A1 (en) 2008-03-03 2009-09-11 Dyax Corp. Metalloproteinase 12 binding proteins
AU2009246166B2 (en) 2008-05-15 2014-09-18 Tetherex Pharmaceuticals Corporation Anti-PSGL-1 antibodies and methods of identification and use
JP2012515556A (ja) 2009-01-23 2012-07-12 バイオジェン・アイデック・エムエイ・インコーポレイテッド 低下したエフェクタ機能を有する安定化Ｆｃポリペプチドおよび使用方法
MX355507B (es) * 2009-03-09 2018-04-19 Bioatla Llc Proteinas mirac.
US10053513B2 (en) 2009-11-30 2018-08-21 Janssen Biotech, Inc. Antibody Fc mutants with ablated effector functions
CN103119054B (zh) 2010-03-26 2017-01-18 达特茅斯大学理事会 Vista调节性t细胞介体蛋白、vista结合剂及其用途
JP6042801B2 (ja) 2010-04-27 2016-12-14 ロシュ グリクアート アーゲー ｍＴＯＲインヒビターとのアフコシル化ＣＤ２０抗体の併用療法
KR20130096731A (ko) * 2010-09-08 2013-08-30 할로자임, 아이엔씨 조건부 활성 치료적 단백질을 평가，확인 또는 진화시키는 방법
EP2718325A4 (en) 2011-06-13 2015-03-11 ABGENOMICS COöPERATIEF U A ANTI-PSGL-1 ANTIBODIES AND USES THEREOF
CA2853412C (en) * 2011-10-28 2021-05-04 University Of Zurich Tdp-43 specific binding molecules
JP6181066B2 (ja) 2011-11-28 2017-08-16 ショー，グレイ，ディー． 新規な増強型セレクチンアンタゴニスト
CA2866612C (en) 2012-03-08 2018-01-16 Halozyme, Inc. Conditionally active ph-dependent cetuximab variant anti-epidermal growth factor receptor antibodies and method of use thereof
CN104619722B (zh) 2012-06-22 2022-10-04 达特茅斯大学理事会 新型vista-ig构建体和vista-ig用于治疗自身免疫性、过敏性和炎性疾病的用途
US9890215B2 (en) * 2012-06-22 2018-02-13 King's College London Vista modulators for diagnosis and treatment of cancer
CA2884704C (en) 2012-09-07 2023-04-04 Randolph J. Noelle Vista modulators for diagnosis and treatment of cancer
SMT201900242T1 (it) 2012-12-03 2019-05-10 Bristol Myers Squibb Co Incremento dell'attivita' anti-cancro di proteine di fuzione a fc immunomodulatrici
AU2014268298B2 (en) 2013-05-24 2019-01-17 Medlmmune, Llc Anti-B7-H5 antibodies and their uses
EP3003390B1 (en) 2013-06-06 2021-07-07 Pierre Fabre Médicament Anti-c10orf54 antibodies and uses thereof
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
EA201690912A1 (ru) 2013-11-05 2016-10-31 Когнейт Биосервисис, Инк. Комбинации ингибиторов контрольных точек и терапевтических средств для лечения рака
US10273301B2 (en) * 2013-12-24 2019-04-30 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments
EP3094346B1 (en) 2014-01-14 2019-12-11 The Trustees Of Dartmouth College Vista antagonist and methods of use
RU2550262C1 (ru) 2014-02-28 2015-05-10 Федеральное государственное унитарное предприятие "Государственный научно-исследовательский институт особо чистых биопрепаратов" Федерального медико-биологического агентства Моноклональное антитело против интерлейкина-6 человека и гибридома, продуцирующая данное моноклональное антитело
WO2015187359A1 (en) 2014-06-04 2015-12-10 Ngm Biopharmaceuticals, Inc. Compositions and methods for targeting a pathway
JP6997619B2 (ja) 2014-06-11 2022-01-17 キャシー・エイ・グリーン 液性免疫の抑制または増進のための、ｖｉｓｔａアゴニスト及びｖｉｓｔａアンタゴニストの使用
EP4079324A1 (en) 2014-07-08 2022-10-26 Sanford-Burnham Medical Research Institute Psgl-1 modulators and uses thereof
JOP20150008B1 (ar) * 2014-11-26 2021-08-17 Janssen Pharmaceutica Nv أجسام مضادة ل vista وأجزاء منها
MX2017007136A (es) 2014-12-05 2017-12-04 Immunext Inc Identificacion de vsig8 como el receptor vista putativo y su uso para producir moduladores vista/vsig8.
KR102693806B1 (ko) 2014-12-11 2024-08-09 피에르 파브르 메디카먼트 항-c10orf54 항체들 및 그들의 용도들
AR103268A1 (es) 2014-12-23 2017-04-26 Bristol Myers Squibb Co Anticuerpos contra tigit
AU2016271111B2 (en) * 2015-05-29 2022-04-28 Bristol-Myers Squibb Company Antibodies against OX40 and uses thereof
EP3722314A1 (en) 2015-06-24 2020-10-14 Janssen Pharmaceutica NV Anti-vista antibodies and fragments
CA3003399A1 (en) 2015-11-02 2017-05-11 Bioatla, Llc Conditionally active polypeptides
WO2017120534A1 (en) 2016-01-08 2017-07-13 Bioalliance C.V. Tetravalent anti-psgl-1 antibodies and uses thereof
US10899836B2 (en) 2016-02-12 2021-01-26 Janssen Pharmaceutica Nv Method of identifying anti-VISTA antibodies
WO2017175058A1 (en) 2016-04-07 2017-10-12 Janssen Pharmaceutica Nv Anti-vista antibodies and fragments, uses thereof, and methods of identifying same
PE20190115A1 (es) 2016-04-15 2019-01-16 Immunext Inc Anticuerpos vista antihumanos y su uso
WO2017181109A1 (en) 2016-04-15 2017-10-19 Michael Molloy Anti-human vista antibodies and use thereof
US11649285B2 (en) 2016-08-03 2023-05-16 Bio-Techne Corporation Identification of VSIG3/VISTA as a novel immune checkpoint and use thereof for immunotherapy
WO2018047143A1 (en) 2016-09-12 2018-03-15 Aurigene Discovery Technologies Limited Vista signaling pathway inhibitory compounds useful as immunomodulators
KR20250159733A (ko) 2017-01-11 2025-11-11 브리스톨-마이어스 스큅 컴퍼니 Psgl-1 길항제 및 그의 용도
PE20250933A1 (es) 2017-03-14 2025-04-02 Five Prime Therapeutics Inc Anticuerpos de union a vista a ph acido
WO2018195772A1 (en) 2017-04-25 2018-11-01 Sun Yat-Sen University Pd-1h as target in treatement of asthma
CA3067835A1 (en) 2017-06-22 2018-12-27 Apexigen, Inc. Anti-vista antibodies and methods of use
CA3079652C (en) 2017-10-20 2022-07-19 Pharmabcine Inc. Anti-vista antibody and use thereof
EP3706798A1 (en) 2017-11-06 2020-09-16 Aurigene Discovery Technologies Limited Conjoint therapies for immunomodulation
US20210085785A1 (en) 2018-02-23 2021-03-25 Truebinding, Inc. Treating cancer by blocking the interaction of vista and its binding partner
SG11202008593PA (en) * 2018-03-21 2020-10-29 Five Prime Therapeutics Inc ANTIBODIES BINDING TO VISTA AT ACIDIC pH
US20190300610A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Pte. Ltd. Vista antigen-binding molecules
WO2019185163A1 (en) 2018-03-29 2019-10-03 Hummingbird Bioscience Holdings Pte. Ltd. Vista antigen-binding molecules
AU2019301120A1 (en) 2018-07-11 2021-02-25 Bristol-Myers Squibb Company Antibodies binding to VISTA at acidic pH
CN109878421B (zh) 2019-03-13 2020-11-03 浙江吉利控股集团有限公司 车辆坡道装置及汽车
CN110563843A (zh) 2019-07-25 2019-12-13 钟小泉 一种靶向人vista蛋白的单克隆抗体

Also Published As

Publication number Publication date
SG11201907848YA (en) 2019-09-27
MX2024003316A (es) 2024-04-04
MY200609A (en) 2024-01-05
JP7573659B2 (ja) 2024-10-25
US20200055936A1 (en) 2020-02-20
JP7211961B2 (ja) 2023-01-24
IL269240B2 (en) 2026-08-01
TW202423986A (zh) 2024-06-16
WO2018169993A1 (en) 2018-09-20
IL269240A (en) 2019-11-28
EP3595720A1 (en) 2020-01-22
KR20240151866A (ko) 2024-10-18
JP2025023919A (ja) 2025-02-19
KR20190128198A (ko) 2019-11-15
EP3595720A4 (en) 2021-05-26
ZA201905525B (en) 2024-12-18
TWI825010B (zh) 2023-12-11
CN110740749A (zh) 2020-01-31
PE20250933A1 (es) 2025-04-02
CN118894937A (zh) 2024-11-05
CO2019010943A2 (es) 2020-01-17
AU2018236218A1 (en) 2019-09-12
US11603406B2 (en) 2023-03-14
JP2020509756A (ja) 2020-04-02
PE20191708A1 (es) 2019-11-28
US20240092907A1 (en) 2024-03-21
TW202615470A (zh) 2026-04-16
AU2018236218B2 (en) 2025-03-06
TWI890190B (zh) 2025-07-11
CN110740749B (zh) 2024-12-10
BR112019019108A2 (pt) 2020-04-22
CA3054067A1 (en) 2018-09-20
AU2025203967A1 (en) 2025-07-03
US20250206822A1 (en) 2025-06-26
IL326895A (en) 2026-04-01
US12195535B2 (en) 2025-01-14
IL269240B1 (en) 2026-04-01
TW201843171A (zh) 2018-12-16
JP2023061927A (ja) 2023-05-02
CL2021002769A1 (es) 2022-08-12
KR102715540B1 (ko) 2024-10-08

Similar Documents

Publication Publication Date Title
CO2019010943A2 (es) Anticuerpos de unión a vista a ph ácido
CO2020012415A2 (es) Anticuerpos de unión a vista a ph ácido
CL2023002543A1 (es) Anticuerpos de unión a vista a ph ácido
MX2021015518A (es) Anticuerpos que se unen a cd39 y sus usos.
ECSP20082648A (es) Anticuerpos anti-sirpa y métodos de utilización de los mismos
CL2022000627A1 (es) Anticuerpos de unión a vista a ph ácido
CL2017003261A1 (es) Factor xi anticuerpos y métodos de uso
BR112018073574A2 (pt) conjugados de anticorpo-fármaco anti-cmet e métodos para a sua utilização
MX2018006787A (es) Anticuerpos que dirigen al receptor fc similar a 5 y metodos de uso.
MX2018003196A (es) Anticuerpos anti-promiostatina o miostatina latente y usos de los mismos.
BR112019005908A2 (pt) uso de combinação de anticorpo anti-pd-1 e inibidor de vegfr na preparação de fármaco para tratamento de cânceres
MX2021001268A (es) Anticuerpos anti-btn3a y su uso en el tratamiento del cáncer o trastornos infecciosos.
BR112018014810A2 (pt) anticorpos anti-fator xi de coagulação
DOP2016000153A (es) Anticuerpos y fragmentos anti-vista
UY36262A (es) Anticuerpos anti proteína similar a angiopoyetina 4 y métodos de uso
UY36261A (es) Anticuerpos anti proteína similar a angiopoyetina-4 (angptl4) y métodos de uso
AR115001A1 (es) ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO
AR115729A1 (es) ANTICUERPOS DE UNIÓN A VISTA EN pH ÁCIDO
AR120024A1 (es) ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO
AR111180A1 (es) ANTICUERPOS DE UNIÓN A VISTA A pH ÁCIDO
CL2022002288A1 (es) Anticuerpos de unión a vista a ph ácido (divisional solicitud 202002410)
EA201992139A1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОМ pH
EA202092208A1 (ru) АНТИТЕЛА, СВЯЗЫВАЮЩИЕСЯ С VISTA ПРИ КИСЛОТНОМ pH
EA202092495A1 (ru) МОДУЛЯТОРЫ Cot И СПОСОБЫ ИХ ПРИМЕНЕНИЯ